{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:52:27Z","timestamp":1785541947793,"version":"3.56.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Several new therapeutic drugs are now available for the management of rheumatoid arthritis (RA). Given that RA has been associated with an increased risk of certain cancers like lymphoma and lung cancer, concern remains about the safety of (newer) immunosuppressants used in RA management as it relates to the risk of cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Most meta-analyses of randomized clinical trials of tumor necrosis factor inhibitors (TNFi) have not observed an association between TNFi and risk of incident cancer. Studies of non-TNFi biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs and cancer are also reassuring but limited and of short-term follow-up. Regarding the use of DMARDs in patients with RA and a prior malignancy, retrospective studies have shown that TNFi use is not associated with recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There is a need for ongoing studies on the safety of non-TNFi bDMARDs and targeted synthetic disease modifying anti-rheumatic drugs and recurrent cancer. Further research is also needed to guide the patients, rheumatologists, and oncologists regarding the safest DMARDs to choose for patients with RA and a recent diagnosis of cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000796","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T01:04:34Z","timestamp":1616202274000},"page":"292-299","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence"],"prefix":"10.1097","volume":"33","author":[{"given":"Namrata","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher I.","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10067-019-04882-x","article-title":"Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?","volume":"39","author":"Fragoulis","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.2008.096487","article-title":"Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies","volume":"69","author":"Sugiyama","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3352","article-title":"Treating rheumatic patients with a malignancy","volume":"13","author":"Elandt","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid Arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann Intern Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other nonbiologic and biologic disease-modifying antirheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","article-title":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R15-20250526","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001241","article-title":"Trends of lymphoma incidence in US veterans with rheumatoid arthritis","volume":"6","author":"Singh","year":"2020","journal-title":"RMD Open"},{"key":"R16-20250526","article-title":"Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype","author":"Hellgren","year":"2020","journal-title":"Rheumatology"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrrheum.2017.81","article-title":"Biologics registers in RA: methodological aspects, current role and future applications","volume":"13","author":"Nikiphorou","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A Nationwide Cohort Study From Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multidatabase real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/acr2.1034","article-title":"Safety of abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials","volume":"1","author":"Simon","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational postmarketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1158\/0008-5472.CAN-09-0415","article-title":"CTLA4 variants, UV-induced tolerance, and risk of nonmelanoma skin cancer","volume":"69","author":"Welsh","year":"2009","journal-title":"Cancer Res"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","volume":"50","author":"Xie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"(5 Suppl 14)","key":"R32-20250526","first-page":"74","article-title":"Preclinical and phase I and II trials of rituximab","volume":"26","author":"Maloney","year":"1999","journal-title":"Semin Oncol"},{"key":"R33-20250526","first-page":"1763","article-title":"Clinical status and optimal use of rituximab for B-cell lymphomas","volume":"12","author":"McLaughlin","year":"1998","journal-title":"Oncology"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14740338.2020.1743263","article-title":"The safety of baricitinib in patients with rheumatoid arthritis","volume":"19","author":"Honda","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R36-20250526","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5\u200ayears: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"R38-20250526","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"101472","DOI":"10.1016\/j.berh.2019.101472","article-title":"The relationships between cancer and autoimmune rheumatic diseases","volume":"34","author":"Cappelli","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2017-212086","article-title":"Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study","volume":"77","author":"Dreyer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5217\/ir.2019.09140","article-title":"Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy","volume":"18","author":"Phan","year":"2020","journal-title":"Intest Res"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"e0143286","DOI":"10.1371\/journal.pone.0143286","article-title":"Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis","volume":"10","author":"Phillips","year":"2015","journal-title":"PLoS One"},{"key":"R45-20250526","article-title":"Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy","author":"Pundole","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumornecrosis factor inhibitors and cancer recurrence in swedish patients with rheumatoid arthritis: A Nationwide Population-Based Cohort Study","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3899\/jrheum.171457","article-title":"Therapy with biologic agents after diagnosis of solid malignancies: results from the corrona registry","volume":"46","author":"Pappas","year":"2019","journal-title":"J Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-019-04874-x","article-title":"Utilization of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer","volume":"39","author":"Pundole","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:19:51Z","timestamp":1748294391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000796","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]}}}